StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Rating) in a research note published on Tuesday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Trading Down 3.7 %
NASDAQ EVOK opened at $2.06 on Tuesday. The stock has a 50-day simple moving average of $2.75 and a 200 day simple moving average of $3.78. The company has a market capitalization of $6.89 million, a PE ratio of -0.72 and a beta of 0.59. The company has a current ratio of 10.65, a quick ratio of 10.45 and a debt-to-equity ratio of 0.70. Evoke Pharma has a 12 month low of $2.03 and a 12 month high of $17.40.
Evoke Pharma (NASDAQ:EVOK – Get Rating) last released its quarterly earnings data on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.71) EPS for the quarter. The company had revenue of $0.46 million during the quarter. Evoke Pharma had a negative net margin of 372.04% and a negative return on equity of 185.09%.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females.
- Get a free copy of the StockNews.com research report on Evoke Pharma (EVOK)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.